Search Results
Found 3 results
510(k) Data Aggregation
(88 days)
Rapid Aortic Measurements (AM) is an image analysis and measurement device to evaluate aortic and iliac arteries in contrast enhanced and non-contrast CT imaging datasets acquired of the chest, abdomen, and/or pelvis. The module segments the aorta, iliacs, and major branching vessels and provides 2D and 3D visualizations of the segmented vessels.
Outputs of the device include: Centerline measurements of the aorta and iliacs, Aortic Zone Measurements (Maximum Oblique Diameter), Fixed Measurements of the aorta and left and right iliacs, 3D Volume Renderings, Rotations, Curved Planar Reformations (CPRs) of the isolated left and right iliacs, aortic oblique Multiplanar Reconstructions (MPRs), and Longitudinal Tracking visualizations.
Rapid Aortic Measurements is an aid to physician decision making. Its results are not intended to be used on a stand-alone basis for clinical decision-making or otherwise preclude clinical assessment.
Rapid Aortic Measurements is indicated for adults.
Precautions/Exclusions:
- Series containing excessive patient motion or metal implants may impact module output quality.
- The AM module will not process series that meet the following module exclusion criteria:
- Series acquired w/cone-beam CT scanners (c-arm CT)
- Series that are non-axial or axial oblique greater than 5 degrees
- Series containing improperly ordered or missing slices where the gap is larger than 3 times the median inter-slice distance (e.g., as a result of manual correction by an imaging technician)
- Series with less than 3cm of target anatomical zones (e.g. aorta or right/left iliac artery)
- NCCT, CECT, CTA, or CTPA datasets with:
- in-plane X and Y FOV < 160mm
- Z FOV (cranio-caudal transverse anatomical coverage) < 144 mm.
- in-plane pixel spacing (X & Y resolution) < 0.3 mm or > 1.0 mm.
- inter-slice distance of < 0.3 mm or > 3 mm.
- slice thickness > 3 mm.
- data acquired at x-ray tube voltage < 70kVp or > 150kVp, including single energy, dual energy, or virtual monochromatic datasets
Rapid Aortic Measurements (AM) is a Software as a Medical Device (SaMD) image processing module and is part of the Rapid Platform. It provides analysis of chest, abdomen, and pelvis non-contrast CT (NCCT), contrast enhanced (CT, CTP (CT- Pulmonary Angiogram, and CTA (CT-Angiography)) for the reconstructed 3D visualization and measurement of arteries from the aortic root to the iliac arteries.
Rapid AM is integrated into the Rapid Platform which provides common functions and services to support image processing modules such as DICOM filtering and job and interface management along with external facing cyber security controls. The Integrated Module and Platform can be installed on-premises within customer's infrastructure behind their firewall or in a hybrid on-premises/cloud configuration. The Rapid Platform accepts DICOM images and, upon processing, returns the processed DICOM images to the source imaging modality or PACS.
Here's a summary of the acceptance criteria and the study proving the device meets them, based on the provided FDA 510(k) clearance letter for "Rapid Aortic Measurements":
Acceptance Criteria and Device Performance
| Acceptance Criteria Category | Specific Metric | Acceptance Criteria | Reported Device Performance | Study Type |
|---|---|---|---|---|
| Segmentation Quality (VR Outputs) | Clinical Accuracy (agreement with source DICOM) | 100% agreement | 100% agreement | Segmentation Quality Study |
| Segmentation Quality (CPR/MPR Outputs) | CPR/MPR Quality | 100% agreement | 100% agreement | Segmentation Quality Study |
| Segmentation Quality (CPR/MPR Outputs) | Anatomical Labeling | 100% agreement between readers for all labels | 100% agreement for all labels | Segmentation Quality Study |
| Segmentation Quality (Zone Measurement Outputs) | Maximum Oblique Diameter Location Accuracy | 100% agreement between readers for all segments | 100% agreement for all segments | Segmentation Quality Study |
| Segmentation Quality (Longitudinal Results) | Clinical Accuracy of Measurements | Clinically accurate measurements placed within respective zones | Deemed clinically accurate | Segmentation Quality Study |
| Segmentation Accuracy (VR Outputs) | Average Dice Coefficient | Not explicitly stated as acceptance criteria, but reported | 0.93 | Segmentation Accuracy Study |
| Segmentation Accuracy (VR Outputs) | Average Hausdorff Distance | Not explicitly stated as acceptance criteria, but reported | 0.54 mm | Segmentation Accuracy Study |
| Segmentation Accuracy (CPR/MPR Visualizations) | Average Hausdorff Distance (centerline accuracy) | Not explicitly stated as acceptance criteria, but reported | 0.59 mm | Segmentation Accuracy Study |
| Segmentation Accuracy (Ground Truth Reproducibility) | Average Dice Coefficient | Not explicitly stated as acceptance criteria, but reported | 0.95 | Segmentation Accuracy Study |
| Measurement Reports | Mean Absolute Error (MAE) compared to ground truth | Not explicitly stated as an acceptance criterion, but reported and stated to "compare favorably with the reference device" | 0.22 cm | Segmentation Accuracy Study |
Study Details:
1. Sample Sizes and Data Provenance:
- Test Set Sample Size: 108 cases from 115 unique patients.
- Data Provenance:
- Country of Origin: 54 US, 24 OUS (Outside US), 30 unknown.
- Retrospective/Prospective: Not explicitly stated, but the description "data used during model training" and "test dataset was independent" suggests a retrospective approach.
2. Number of Experts and Qualifications for Ground Truth (Test Set):
- Number of Experts: Up to three clinical experts (for segmentation quality/clinical accuracy). The number of experts involved in establishing ground truth for quantitative segmentation and measurement accuracy metrics is not explicitly stated but implies expert involvement.
- Qualifications of Experts: Not explicitly stated beyond "clinical experts."
3. Adjudication Method (Test Set):
- Adjudication Method: "Consensus of up to three clinical experts" for the segmentation quality/clinical accuracy endpoint. For other endpoints where "agreement between readers" is mentioned, it implies a consensus or agreement-based adjudication. No specific scheme like "2+1" or "3+1" is detailed.
4. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:
- Was it done? No, an MRMC comparative effectiveness study was not explicitly mentioned. The FDA letter describes standalone device performance against ground truth and expert consensus.
- Effect Size of Human Readers with/without AI: Not applicable, as an MRMC study was not conducted or reported.
5. Standalone Performance Study:
- Was it done? Yes, both a "Segmentation Quality Study" and a "Segmentation Accuracy Study" were conducted to assess the algorithm's standalone performance. The results reported in the table above are from these standalone evaluations.
6. Type of Ground Truth Used:
- Ground Truth Type:
- Expert Consensus: Used for segmentation quality and clinical accuracy, determined by the "consensus of up to three clinical experts against the source DICOM images."
- Approved Ground Truth Segmentations: For measurement reports, AM measurements were compared to "measurements taken from approved ground truth segmentations using a validated technique." This implies expert-derived and validated segmentations serve as the reference for measurements.
7. Sample Size for Training Set:
- Training Set Sample Size: Not explicitly stated. The document mentions "The test dataset was independent from the data used during model training," but does not provide details on the size of the training dataset itself.
8. How the Ground Truth for the Training Set was Established:
- How Ground Truth Established: Not explicitly stated in the provided text. The document only mentions that the test dataset was independent from the training data.
Ask a specific question about this device
(172 days)
Rapid is an image processing software package to be used by trained professionals, including but not limited to physicians (medical analysis and decision making) and medical technicians (administrative case processing). The software runs on a standard off-the-shelf computer or a virtual platform, such as VMware, and can be used to perform image viewing, processing, and analysis of images. Data and images are acquired through DICOM compliant imaging devices. Rapid is indicated for use in Adults only.
Rapid provides both viewing and analysis capabilities for functional and dynamic imaging datasets acquired with CT, CT Perfusion (CTP), CT Angiography (CTA), C-arm CT Perfusion and MRI including a Diffusion Weighted MRI (DWI) Module and a Dynamic Analysis Module (dynamic contrast-enhanced imaging data for MRI, CT, and C-arm CT).
Rapid C-arm CT Perfusion can be used to qualitatively assess cerebral hemodynamics in the angiography suite.
The CT analysis includes NCCT maps showing areas of hypodense and hyperdense tissue.
The DWI Module is used to visualize local water diffusion properties from the analysis of diffusion - weighted MRI data.
The Dynamic Analysis Module is used for visualization and analysis of dynamic imaging data, showing properties of changes in contrast over time. This functionality includes calculation of parameters related to tissue flow (perfusion) and tissue blood volume.
Rapid CT Perfusion and Rapid MR Perfusion can be used by physicians to aid in the selection of acute stroke patients (with known occlusion of the intracranial internal carotid artery or proximal middle cerebral artery). Instructions for the use of contrast agents for this indication can be found in Appendix A of the User's Manual. Additional information for safe and effective drug use is available in the product-specific iodinated CT and gadolinium-based MR contrast drug labeling.
In addition to the Rapid imaging criteria, patients must meet the clinical requirements for thrombectomy, as assessed by the physician, and have none of the following contraindications or exclusions:
· Bolus Quality: absent or inadequate bolus.
· Patient Motion: excessive motion leading to artifacts that make the scan technically inadequate.
· Presence of hemorrhage.
· C-Arm CTP is not to be used in the Rapid Thrombectomy indication criteria, other modalities should be consulted.
Cautions:
· C-Arm CTP provides qualitative data only, review other modalities prior to diagnosis. CBV and CBT are not absolute and CBT, CBV, MTT and Tmax are supported for qualitative interpretation of the perfusion maps only.
Rapid is a software package that provides for the visualization and study of changes in tissue using digital images captured by diagnostic imaging systems including CT (Computed Tomography) and MRI (Magnetic Image Resonance), as an aid to physician diagnosis.
Rapid can be installed on a customer's Server or it can be accessed online as a virtual system. It provides viewing, quantification, analysis and reporting capabilities.
Rapid works with the following types of (DICOM compliant) medical image data:
- CT (Computed Tomography)
- MRI(Magnetic Image Resonance) ●
Rapid acquires (DICOM compliant) medical image data from the following sources:
- . DICOM file
- DICOM CD-R ●
- Network using DICOM protocol. ●
Rapid provides tools for performing the following types of analysis:
- selection of acute stroke patients for endovascular thrombectomy ●
- volumetry of thresholded maps
- time intensity plots for dynamic time courses
- measurement of mismatch between labeled volumes on co-registered image ● volumes
- large vessel density. ●
Rapid is a Software as a Medical Device (SaMD) consisting of one or more Rapid Servers (dedicated or virtual). The Rapid Server is an image processing engine that connects to a hospital LAN, or inside the Hospital Firewall. It can be a dedicated Rapid Server or a VM Rapid appliance, which is a virtualized Rapid Server that runs on a dedicated server.
Rapid is designed to streamline medical image processing tasks that are time consuming and fatiguing in routine patient workup. Once Rapid is installed it operates with minimal user interaction. Once the CT [NCCT, CT, CTA, C-arm CT(CBCT)] or MR (MR, MRA) data are acquired, the CT or MRI console operator selects Rapid as the target for the DICOM images, and then the operator selects which study/series data to be sent to Rapid. Based on the type of incoming DICOM data, Rapid will identify the data set scanning modality and determine the suitable processing module. The Rapid Platform is a central unit which coordinates the execution image processing modules which support various analysis methods used in clinical practice today:
- Rapid CTP/MRP/C-arm CTP, DWI, Dynamic Analysis (Original: K121447, Updated ● with K172477, K182130, K213165, K233512 and K233582)
- Rapid CTA (K172477) ●
- Rapid ASPECTS (K200760, K232156)
- Rapid ICH (K193087, K221456)
- Rapid LVO (K200941, K221248)
- Rapid NCCT Stroke (K222884)
- . Rapid RV/LV (K223396)
- Rapid PETN (K220499)
- Rapid ANRTN (K230074) ●
- Rapid SDH (K232436) ●
The iSchemaView Server is a dedicated server that provides a central repository for Rapid data. All iSchemaView Server data is stored on encrypted hard disks. It also provides a user interface for accessing Rapid data. It connects to a firewalled Data Center Network and has its own firewall for additional cyber/data security. The iSchemaView Server connects to one or more Rapid Servers via WAN. Available types of connection include VPN (Virtual Private Network - RFC2401 and RFC4301 Standards) Tunnel and SSH (Secure Shell).
The provided text describes the iSchemaView Rapid device, an image processing software package. The document focuses on its 510(k) submission (K233582) and demonstrates its substantial equivalence to a previously cleared predicate device (K213165). The new submission primarily extends the device's functionality to include C-arm CT for qualitative cerebral hemodynamics assessment and qualitative analysis of perfusion parameters.
Here's an analysis of the acceptance criteria and the study that proves the device meets them, based on the provided text:
1. A table of acceptance criteria and the reported device performance
The document does not explicitly present a "table of acceptance criteria" with corresponding "reported device performance" in the format typically used for performance studies with specific metrics and thresholds (e.g., sensitivity, specificity, accuracy). Instead, it states that the device was validated to provide "accurate representation of key processing parameters" and "met all design requirements and specifications."
The key performance claims and their validation are described qualitatively:
| Acceptance Criterion (Implied) | Reported Device Performance |
|---|---|
| Accurate representation of key processing parameters for perfusion imaging (conventional CT and C-arm CT) | "The performance validation testing demonstrated that the Rapid system provides accurate representation of key processing parameters under a range of clinically relevant parameters and perturbations associated with the intended use of the software." (Page 8) "Phantom validation results between conventional CT and C-arm CT scanners for the perfusion indication of Rapid Core are comparable with small biases in MTT (mean transit time) and Tmax (time to the maximum of the residue function) which were expected due to the temporal resolution difference in conventional and C-arm CT scanners." (Page 9) |
| Meet all design requirements and specifications | "Software performance, validation and verification testing demonstrated that the Rapid system met all design requirements and specifications." (Page 8) |
2. Sample size used for the test set and the data provenance
The document states that iSchemaView conducted "extensive phantom validation testing" and "software verification and validation testing of the Rapid system" using "the use of phantoms and case data." However, it does not specify the sample size for the test set (number of phantoms or cases).
The data provenance is stated as:
- Phantoms: Used for characterizing perfusion imaging performance.
- Case Data: Used for validating the Rapid System performance.
The document does not explicitly mention the country of origin of the data or whether it was retrospective or prospective.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
The document does not specify the number of experts used to establish ground truth for the test set or their specific qualifications. It mentions that the device is "to be used by trained professionals, including but not limited to physicians (medical analysis and decision making) and medical technicians (administrative case processing)" and that "Rapid C-arm CT Perfusion can be used to qualitatively assess cerebral hemodynamics in the angiography suite." While this indicates the intended users, it does not explicitly detail the experts involved in establishing ground truth for the validation studies.
4. Adjudication method for the test set
The document does not mention any adjudication method (e.g., 2+1, 3+1) used for establishing ground truth in the test set.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
The document does not describe an MRMC comparative effectiveness study where human readers' performance with and without AI assistance was evaluated. The current submission focuses on demonstrating substantial equivalence and the performance of the device itself (including its new feature for C-arm CT) rather than its direct comparative effectiveness with human readers.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
The provided text only discusses "extensive phantom validation testing" and "software verification and validation testing." The results presented ("accurate representation of key processing parameters," "met all design requirements and specifications," and "comparable with small biases") appear to be from an algorithm-only (standalone) performance assessment, particularly for the software's ability to process and represent data from phantoms and cases, and the comparability of C-arm CT processing to conventional CT. There is no mention of human-in-the-loop performance in the context of these validation studies.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
For the "phantom validation testing," the ground truth would inherently be known physical and temporal parameters designed into the phantoms.
For the "case data," the document does not explicitly state the type of ground truth. Given the nature of a software processing and analysis system, it likely relies on a combination of:
- Established interpretations from other modalities or clinical diagnoses, particularly for "selecting acute stroke patients."
- Quantitative measurements derived from advanced imaging, which the software aims to replicate or analyze.
8. The sample size for the training set
The document does not specify the sample size for the training set. It details the device's functionality and validation rather than its development or machine learning training specifics.
9. How the ground truth for the training set was established
Since the document does not mention the sample size for the training set, it also does not describe how the ground truth for the training set was established. The focus is on the validation of the developed software, which includes algorithms, some of which may be AI/ML-based as indicated by "Mixed Traditional and AI/ML" under Software in Table 1 (page 10). However, the specifics of ML model training, including data and ground truth establishment, are not detailed in this summary.
Ask a specific question about this device
(76 days)
Rapid is an image processing software package to be used by trained professionals,including but not limited to physicians and medical technicians. The software runs ona standard off-the-shelf computer or a virtual platform, such as VMware, and can be used to perform image viewing, processing and analysis of images. Data and images are acquired through DICOM compliant imaging devices.
Rapid provides both viewing and analysis capabilities for functional and dynamic imaging datasets acquired with CT Perfusion (CTP). CT Angiography (CTA), and MRI including a Diffusion Weighted MRI (DWI) Module and a Dynamic Analysis Module (dynamic contrast-enhanced imaging data for MRI and CT).
The CT analysis includes NCCT maps showing areas of hypodense and hyperdense tissue.
The DWI Module is used to visualize local water diffusion properties from the analysis of diffusion weighted MRI data.
The Dynamic Analysis Module is used for visualization and analysis of dynamic imaging data, showing properties of changes in contrast over time. This functionality includes calculation of parameters related to tissue flow (perfusion) and tissue blood volume.
Rapid CT-Perfusion and Rapid MR-Perfusion can be used by physicians to aid in the selection of acute stroke patients (with known occlusion of the intracranial internal carotid artery or proximal middle cerebral artery)Instructions for the use of contrast agents for this indication can be found in Appendix A of the User's Manual. Additional information for safe and effective drug use is available inthe product-specific iodinated CT and gadolinium-based MR contrast drug labeling.
In addition to the Rapid imaging criteria, patients must meet the clinical requirements for thrombectomy, as assessed by the physician, and have none of the following contraindications or exclusions:
- · Bolus Quality: absent or inadequate bolus.
- · Patient Motion: excessive motion leading to artifacts that make the scan technically inadequate
- Presence of hemorrhage
Rapid is a software package that provides for the visualization and study of changes in tissue using digital images captured by diagnostic imaging systems including CT (Computed Tomography) and MRI (Magnetic Image Resonance), as an aid to physician diagnosis. Rapid can be installed on a customer's Server or it can be accessed online as a virtual system. It provides viewing, quantification, analysis and reporting capabilities.
Rapid is a Software as a Medical Device (SaMD) consisting of one or more Rapid Servers (dedicated or virtual) in on-premises or hybrid (on-premises/cloud) configurations. The Rapid Server is an image processing engine that connects to a hospital LAN, or inside the Hospital Firewall in the on-premises configuration or in conjunction with a secure link to the cloud in the hybrid configuration. It can be a dedicated Rapid Server or a VM Rapid appliance, which is a virtualized Rapid Server that runs on a dedicated server.
Rapid is designed to streamline medical image processing tasks that are time consuming and fatiguing in routine patient workup. Once Rapid is installed it operates with minimal user interaction. Once the CT (NCCT, CT, CTA) or MR (MR, MRA) data are acquired, the CT or MRI console operator selects Rapid as the target for the DICOM images, and then the operator selects which study/series data to be sent to Rapid. Based on the type of incoming DICOM data. Rapid will identify the data set scanning modality and determine the suitable processing module. The Rapid platform is a central control unit which coordinates the execution image processing modules which support various analysis methods used in clinical practice today.
Here's an analysis of the provided text to fulfill your request, noting that the document is an FDA 510(k) clearance letter and summary, which typically focuses on demonstrating substantial equivalence to a predicate device rather than presenting a detailed de novo device performance study. Therefore, some of the requested information (like specific effect sizes from MRMC studies or detailed ground truth establishment for a training set) might not be explicitly present if the submission didn't require entirely new clinical performance data for clearance.
Key Observation from the Document:
The document (K233512) is a 510(k) summary for iSchemaView Rapid (6.0), claiming substantial equivalence to a previously cleared predicate device, Rapid (K213165). The primary change appears to be an "extension of installation in a hybrid configuration (on-premises and hybrid)." This implies that extensive new clinical performance studies for the core functionality may not have been required, as the device is deemed "as safe and effective as the previously cleared Rapid (K213165) with an extension of installation in a hybrid configuration."
Given this, the "acceptance criteria" and "study that proves the device meets the acceptance criteria" are largely framed around demonstrating equivalence to the predicate and ensuring the new configuration doesn't introduce new safety or effectiveness concerns.
Acceptance Criteria and Device Performance (Based on the provided document)
Since this is a 510(k) submission for substantial equivalence based on a predicate, the "acceptance criteria" are implied to be that the device performs equivalently to the predicate and any new features (like hybrid configuration) do not negatively impact safety or effectiveness. The document highlights software verification and validation as the primary means of demonstrating compliance.
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria (Implied from Section 510(k) Summary and "Performance Data") | Reported Device Performance (as stated in the document) |
|---|---|
| Functional Equivalence to Predicate Device: - Image viewing, processing, and analysis of CT/MRI images for functional and dynamic imaging datasets. - Specific modules: CT-Perfusion, MR-Perfusion, DWI, Dynamic Analysis, NCCT maps (hypodense/hyperdense tissue), CTA. - Aid in selection of acute stroke patients (with known occlusion of intracranial ICA or proximal MCA). - Calculation of parameters related to tissue flow (perfusion) and tissue blood volume. | "Rapid has the same intended use and similar indications, technological characteristics and principles of operation as its predicate devices." "Rapid is as safe and effective as the previously cleared Rapid (K213165) with an extension of installation in a hybrid configuration..." |
| Technical Compliance: - DICOM compliance. - Operates on standard off-the-shelf computers or virtual platforms. - Handles DICOM medical image data (CT, MRI) from various sources. - Secure communication protocols (SMTP with security extensions, VPN, SSH). | "Rapid complies with DICOM (Digital Imaging and Communications in Medicine) - Developed by the American College of Radiology and the National Electrical Manufacturers Association. NEMA PS 3.1 - 3.20." "Rapid is a DICOM-compliant PACS software..." "Rapid runs on standard 'off-the-shelf' computer and networking hardware." "Rapid generally connects to the infrastructure of the medical partner... Rapid uses a SMTP protocol with security extensions to provide secure communications." "Available types of connection include VPN (Virtual Private Network - RFC2401 and RFC4301 Standards) Tunnel and SSH (Secure Shell)." |
| Performance Accuracy & Reliability: - Accurate representation of key processing parameters. - Handles clinically relevant parameters and perturbations. - Meets all design requirements and specifications. | "iSchemaView conducted extensive performance validation testing and software verification and validation testing of the Rapid system." "This performance validation testing demonstrated that the Rapid system provides accurate representation of key processing parameters under a range of clinically relevant parameters and perturbations associated with the intended use of the software." "Software performance, validation and verification testing demonstrated that the Rapid system met all design requirements and specifications." "The Rapid System performance has been validated with phantom and case data." |
| Safety & Effectiveness (no new issues compared to predicate): - Compliance with QSR (21 CFR Part 820.30). - Risk management (EN ISO 14971:2019). - Software lifecycle processes (IEC 62304:2016). - Usability engineering (IEC 62366:2015). | "Rapid has been designed, verified and validated in compliance with 21 CFR, Part 820.30 requirements. The device has been designed to meet the requirements associated with EN ISO 14971:2019 (risk management)." "Rapid raises no new issues of safety or effectiveness compared to Rapid (K2131650), as demonstrated by the testing conducted with Rapid." |
2. Sample Size Used for the Test Set and Data Provenance
The document mentions "The Rapid System performance has been validated with phantom and case data." However, it does not specify the sample size for the test set of "case data" or "phantom data", nor does it specify the country of origin or whether the data was retrospective or prospective. For a 510(k), particularly one proving substantial equivalence to a predicate, new large-scale clinical studies are not always required if software verification and validation suffice, as implied here.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications
The document states, "The primary users of Rapid software are medical imaging professionals who analyze tissue using CT or MRI images." However, it does not specify the number of experts used to establish ground truth for the test set, nor does it provide their specific qualifications (e.g., number of years of experience, specific board certifications). It only generically refers to "trained professionals, including but not limited to physicians and medical technicians."
4. Adjudication Method for the Test Set
The document does not specify any adjudication method (e.g., 2+1, 3+1) used for the test set.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
The document does not indicate that a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was done comparing human readers with AI vs. without AI assistance, nor does it state an effect size for such an improvement. The focus is on the device's standalone performance and its equivalence to the predicate.
6. If a Standalone Performance Study (Algorithm Only Without Human-in-the-Loop Performance) Was Done
Yes, the document implies that a standalone performance evaluation of the algorithm's core processing capabilities was conducted. It states: "iSchemaView conducted extensive performance validation testing and software verification and validation testing of the Rapid system. This performance validation testing demonstrated that the Rapid system provides accurate representation of key processing parameters under a range of clinically relevant parameters and perturbations associated with the intended use of the software." This refers to the algorithm's performance in processing images and generating analyses.
7. The Type of Ground Truth Used
The document states, "The Rapid System performance has been validated with phantom and case data." This suggests that the ground truth for "phantom data" would be known physical or simulated values. For "case data," the document does not explicitly state the type of ground truth, such as expert consensus, pathology, or outcomes data. However, given the context of stroke patient selection, clinical outcomes or expert consensus on imaging findings would typically be relevant for such applications.
8. The Sample Size for the Training Set
The document does not provide any information regarding the sample size used for the training set. As this is a 510(k) for an updated version of an existing device, it's possible that the training data for the core AI components was part of earlier development and was not re-evaluated for this specific submission, or that detailed training data was not a required element for this type of substantial equivalence claim.
9. How the Ground Truth for the Training Set Was Established
The document does not provide any information on how the ground truth for the training set was established.
Ask a specific question about this device
Page 1 of 1